COVID-19 serological survey using micro blood sampling

Melissa M. Matthews[1†], Tae Gyun Kim[1†], Satoshi Shibata[1†], Noriko Shibata[1], Christian Butcher[2], Jaekyung Hyun[1], Keon Young Kim[1], Theodore Robb[3], Siang Sheng Jheng[3], Masashi Narita[4], Tomoari Mori[5], Mary Collins[6] & Matthias Wolf[1]*

[1]Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.

[2]Fluid Mechanics Unit, OIST, Onna-son, Okinawa, Japan.

[3]IT Division, Infrastructure Section, OIST, Onna-son, Okinawa, Japan.

[4]Okinawa Chubu Hospital, Division of Infectious Diseases, Okinawa City, Okinawa, Japan

[5]Research Support Division, Occupational Health and Safety, OIST, Onna-son, Okinawa, Japan.

[6]Research Support Division, Office of the Provost, OIST, Onna-son, Okinawa, Japan.

[†]these authors have contributed equally

*Correspondence to *matthias.wolf@oist.jp*

Abstract

During August 2020, we carried out a serological survey among students and employees at the Okinawa Institute of Science and Technology Graduate University (OIST), Japan, testing for the presence of antibodies against SARS-CoV-2, the causative agent of COVID-19. We used a FDA-authorized 2-step ELISA protocol developed by the Krammer Lab (*1*, *2*) in combination with at-home self-collection of blood samples using a custom low-cost finger prick-based capillary blood collection kit. Although our survey did not find any COVID-19 seropositive individuals among the OIST cohort, it reliably detected all positive control samples obtained from a local hospital and excluded all negatives controls. Among our controls, we found strong cross-reactivity of antibodies in samples from a serum pool from two MERS patients in the anti-SARS-CoV-2-S ELISA. Here we show that a centralized ELISA in combination with patient-based capillary blood collection using as little as one drop of blood can reliably assess

the seroprevalence among communities. Anonymous sample tracking and an integrated website created a stream-lined procedure. Major parts of the workflow were automated on a liquid handler, demonstrating scalability. We anticipate this concept to serve as a prototype for reliable serological testing among larger populations.

Background and Introduction

At the beginning of 2020, COVID-19 emerged from Hubei province in southern China and quickly spread across the globe. Due to its proximity and direct flight connections between the epicenter in Wuhan and its capital Tokyo, the Japanese Nation was among the first to experience cases of the disease outside China, documenting its first case on January 15, 2020. In early April, as the tourism season in Okinawa began to ramp up, so did the new cases of COVID-19 in Okinawa. A first wave of COVID-19 cases peaked at the moderate rate of 10 cases/day in mid-April (total number 132 cases), which was effectively reduced by 5 weeks of lock-down measures to no additional cases within the next two months. From early August on, however, a second, much stronger wave of infections has, at the time of this report, culminated in more than 2,682 accumulated cases on the island (October 8, 2020). The present study was conducted at the beginning of this second wave.

Serological surveys which detect the presence of antibodies against SARS-CoV-2 antigens can provide important information to the government for issuing health care guidelines. At the beginning of April 2020, we obtained plasmids for coronavirus surface antigens from the Krammer Lab at the Icahn School of Medicine (NY, NY, USA). We established protein expression and purification in a mammalian cell line and set up an ELISA following the 2-step assay developed by the same group (*1*). Their assay has received emergency use authorization by the U.S. Food & Drug Administration (FDA) (*2*). We secured PCR-confirmed human sera from COVID-19 positive patients at the local hospital as well as negative controls from serum collected before December 2019. Once the assay itself was validated, we set up partially automated sample handling on a robotic liquid handler, established a website with a barcoding system for anonymous sample tracking, and conducted a serological survey of staff and students at our institution.

In emergency situations such as during COVID-19, the health care system is under stress; it cannot be expected that trained clinical personnel are available to draw patient blood by venous puncture. Furthermore, non-essential human traffic in hospitals and other health care institutions should ideally be limited to protect vital health care workers from risk of exposure to potential carriers of the virus. To overcome this limitation, we distributed easy-to-use, self-administered micro blood sampling kits to participants. The kit uses a single-use safety lancet to collect a few drops of capillary blood from the participant's finger. We show that antibody titers obtained by micro blood sampling are equivalent to serum antibody titers from blood drawn by conventional venous puncture. This low-cost, easily deployable self-sampling method in combination with a highly sensitive and specific ELISA in a centralized testing lab provides a scalable solution that can enable serological surveys of larger populations.

Methods

Protein Expression and Purification

Plasmids for mammalian expression of the SARS-CoV-2 S (spike) protein receptor-binding domain (RBD, residues 319-541) and stabilized His-tagged SARS-CoV-2 S including a T4 foldon trimerization tag were generously provided by Florian Krammer and colleagues at the Icahn School of Medicine (NY, NY, USA) (*3*). Proteins were expressed in Expi293F cells and purified by Ni-NTA affinity and size-exclusion chromatography as described previously (*1*). The yield was 15 mg/L and 4 mg/L for RBD and the trimeric SARS-CoV-2 S, respectively. 500 µL aliquots of purified protein at a concentration of 10 µg/mL were frozen in liquid nitrogen and stored at -80 °C until use. We expressed and purified both the SΔcs (furin cleavage site deletion RRAR to A) and SΔcspp construct (cleavage site deletion and stabilizing mutations K986P and V987P) (*3*), but only the SΔcs protein was used in this study. Protein purity was verified by SDS-PAGE and confirmed by Western blot with MonoRab™ Anti-His Tag (C-term) Antibody (Nr. 25B6E11, GenScript, USA).

Electron microscopy

The quality and folding of two proteins, the RBD and SARS-CoV-2 S, were verified by biochemical methods and correct folding and assembly of the trimeric spike protein was

93 confirmed using cryo-electron microscopy (Figure 1). Sample solution was applied to a carbon
94 coated copper grid and stained with 1 % uranyl acetate. The protein particles were visualized
95 with a Talos L120 transmission electron microscope (Thermo Fisher Scientific, USA) operating
96 at 120 kV acceleration voltage.

97 For cryo-EM, 3 µL of purified trimeric spike sample solution was applied to UltrAuFoil
98 R1.2/1.3 grids pre-treated with a Solarus advanced plasma system (Model 950, Gatan, USA)
99 for 60 seconds at 25 °C in a 23 % H_2, 77 % O_2 gas mix. The grids were blotted and vitrified in a
100 Vitrobot Mark IV (Thermo Fisher Scientific, USA) using a liquid ethane-propane mixture. Cryo-
101 EM grids and particle density were optimized by screening based on protein concentration in
102 the range of 2-3 mg/mL. Particles Images of trimeric spike protein in amorphous ice were
103 collected with a Titan Krios transmission electron microscope (Thermo Fisher Scientific, US)
104 operating at 300 kV on a Falcon-3EC camera (Thermo Fisher Scientific, US) in counting mode,
105 at a pixel size of 1.08 Å (at the specimen level). Frames from 1,479 movies were aligned, dose-
106 weighted and summed using motioncor2 (*4*). Contrast transfer function (CTF) estimation,
107 particle picking and 2D classification were performed with RELION 3.1 (*5*). A total of 1,119,504
108 particles were picked semi-automatically, of which 297,144 particles were retained after 2D
109 classification.

110

111 *Sample collection and heat inactivation*

112 The micro blood sampling kits were assembled in 8x12 cm sealable plastic bags, including BD
113 Microtainer® contact-activated lancet (Becton Dickison, NJ, USA), blood collection tube
114 containing a coagulant and a separator gel (Greiner Bio-one MiniCollect® TUBE 0.5/0.8 CAT
115 Serum Separation Clot Activator gold cap), packaged alcohol wipes, adhesive bandage, and
116 peelable sticker with a linear tube barcode (Code 128) and a matching QR code encoding a
117 link to our website. After finger prick with the safety lancet, users collected 1-5 drops (approx.
118 30-150 µL) of capillary blood into the serum separation tube and attached the linear barcode.
119 Serum separation tubes were centrifuged at 5,000 × g for 5 min at 4 ^{o}C under biosafety level
120 2 (BSL2) conditions, then inactivated in a water bath at 56 ^{o}C for 1 hr. Heat-inactivated
121 samples were stored at 4 ^{o}C until use for ELISA. After scanning tube barcodes for each plate

122 into a CSV file with a hand-held scanner, separated serum was transferred into barcoded 96-
123 well plates using manual pipetting.
124
125 *ELISA and automation*
126 We followed the 2-step ELISA protocol developed by the Krammer lab (*1*). ELISA plate formats
127 were modified as depicted in Supplemental Figure 1C. Modified plate designs included two
128 dilution series of positive control, which provided an internal standard. Additional negative
129 controls were included to provide a cutoff that was consistently within the suggested range
130 of 0.15-0.2 AU (Absorbance Units) at 492 nm.
131 We implemented a partially automated workflow on a Beckman Biomek FX^{P} (Beckman
132 Coulter, Indianapolis, IN, USA) liquid handling robot for two steps of the ELISA protocol,
133 namely, for (i) dilution and transfer of serum samples for RBD screening plates and for (ii)
134 plate developing and reading of all plates. Plates were stacked to maximize throughput and
135 usage of available deck space. Automated dilution and transfer of serum samples utilized a
136 96-well plate containing 5X diluted serum in PBS, termed the D1 (dilution 1) plate as a source
137 plate. Sample from the D1 plate was diluted with a PBS-T milk solution in a second 96-well
138 plate, termed the D2 (dilution 2) plate, and finally transferred to the destination ELISA plate
139 according to the published protocol (*1*). After dilution, D1 plates were immediately wrapped
140 in parafilm and stored at 4 ^{o}C. If a given sample tested positive against RBD antigen in step 1,
141 a fresh 5x diluted sample was prepared using solution remaining in the serum separation
142 tubes. If the volume of the remaining serum was insufficient, the 5x diluted sample from the
143 D1 plate was used for the confirmatory step 2.
144 For automated plate development and reading, 100 µL of Sigma*Fast*™ OPD
145 development solution (Sigma Aldrich) was prepared according to the described protocol and
146 added to all wells. A wait time was programmed in the liquid handler workflow so that exactly
147 10 minutes after addition of OPD, 50 µL of 3 M HCl were added to quench the reaction.
148 Immediately after addition of HCl to a given plate, the plate was automatically loaded into
149 and read on a DTX800 multimode plate reader (Beckman Coulter, Indianapolis, IN, USA) at
150 492 nm wavelength. Functions were added within the automation code to automatically
151 calculate threshold values for each plate and output a “positive” or “negative” result for each

152 sample. All other steps, including washing on an AquaMax 4000 plate washer (Molecular
153 Devices LLC, San Jose, CA, USA), were carried out manually.
154
155 *Controls and Standards*
156 Three positive controls in the form of intravenous blood sera from confirmed SARS-CoV-2
157 PCR-positive patients (collected 10-30 days post onset of symptoms) were obtained from
158 Naha Municipal Hospital, Naha, Japan. After titer analysis of all three samples (data not
159 shown), the two samples with the strongest titers were pooled and used as the positive
160 control for all assays. Positive controls (collected at least 90 days after onset of symptoms)
161 for validation of the capillary blood collection method were obtained from Okinawa Chubu
162 Hospital, Uruma City, Japan. Negative controls taken from patients prior to November 2019
163 were obtained from Naha Municipal Hospital from intravenous blood, and from a commercial
164 serum pool (Human Serum from human male AB plasma, Sigma Aldrich H4522-100ML, Batch
165 #SLCD1948, serum was pooled prior to August 2019). Human MERS-convalescent serum and
166 SARS-CoV-2 convalescent plasma (NIBSC code 20/130) were obtained from the National
167 Institute of Biological Standards and Control, UK.
168
169 *Calculation of thresholds*
170 The threshold for each step 1 plate was defined as the average of the negative controls plus
171 3 standards deviations of the negative controls as described previously (*1*). The average and
172 median threshold for all step 1 plates was 0.161 AU and 0.166 AU, respectively. Initially, the
173 threshold for the step 2 plate was calculated in the same manner as step 1. However, the
174 threshold calculated with only three negative controls was below the recommended range
175 (0.15-0.2 AU at 492 nm). Therefore, another threshold, calculated as 4-times the average
176 blank, which has been demonstrated to be valid for identifying anti-SARS-CoV-2 antibody-
177 positive samples was used instead (*6*). Average and median threshold for all step 2 plates
178 were 0.196 AU and 0.1868 AU, respectively.
179
180 *Calculation of predictivity values*
181 The positive predictivity value (PPV) describes the likelihood that a sample which tests
182 positive is a true positive. The negative predictivity value (NPV) describes the likelihood that

183 a sample which tests negative is a true negative (*7*). Estimated predictivity values were
184 calculated using the following equations:
185
186 $$positive\ predictivity\ value = \frac{sensitivity \times prevalence}{(sensitivity \times prevalence) + (1 - specificity)(1 - prevalence)}$$
187
188
189 $$negative\ predictivity\ value = \frac{specificity \times (1 - prevalence)}{[(1 - sensitivity) \times prevalence] + [specificity \times (1 - prevalence)]}$$
190
191
192 *Website-based platform for test application and anonymous results reporting*
193 Test results were disseminated using a custom web application developed by the OIST IT
194 section and deployed through Microsoft Azure cloud. The front page (Supplementary Figure
195 1B) contained a disclaimer, an instructional video (Supplemental Information), a printable
196 instruction sheet, and other basic information for participants.
197 The QR code printed and included in each blood sample collection kit was encoded
198 with a unique web URL corresponding to the sample ID of the sticker placed on the sample
199 tube (Supplemental Figure 1A). Following a simple user flow (Supplemental Figure 2),
200 participants could check their test results anonymously either by scanning the QR code with
201 a smartphone or by entering the 6-digit sample ID matching the linear tube barcode.
202 Upon inputting a valid sample ID, participants were prompted to accept a disclaimer
203 before viewing results. After accepting the disclaimer, participants were able to retrieve the
204 status of their sample, including guidance on interpreting test results. Optional information
205 about gender, prior symptoms, age, travel history could be entered voluntarily. This metadata
206 was collected anonymously through a survey on the SurveyMonkey
207 (https://www.surveymonkey.com*)* platform and linked to the sample ID which was passed as
208 a hidden field via the participant's web browser. Each sample ID was stored in a database
209 table along with values representing test results and disclaimer acceptance. The web
210 application queried this database to retrieve the status of the requested sample ID. The
211 sample IDs were composed of six characters generated randomly from the set of
212 alphanumeric characters (a-zA-Z0-9), excluding letters O, I, l, Z, Q and numbers 0, 1, 2, 9 to

213 minimize human read errors. Out of approximately 10^{10} combinations, 1000 unique IDs were
214 randomly selected. Some additional security features, such as request rate limiting, were
215 implemented to restrict the use of automated tools to retrieve results for all possible sample
216 IDs. Basic functions were developed to allow batch import and export of test results in a
217 delimited text format, allowing easy transfer of data between the testing system and the web
218 application database.
219
220 *Sequence alignments*
221 The full-length sequences of SARS-CoV, MERS-CoV S protein (UniProt ID: P59594 and K9N5Q8,
222 respectively) were aligned pairwise using ClustalW2, against the SΔcs sequence (*3*)
223 (Supplementary Figure 3).
224
225 *Human subject research approval*
226 The experiments were conducted according to a proposal approved by the OIST human
227 subjects ethics committee (application HSR-2020-026).
228
229 **Results**
230
231 *Protein preparation and validation*
232 SARS-CoV-2 trimeric spike and its receptor-binding domain (RBD) were expressed in
233 mammalian cells and purified. The quality was verified by Western blot and electron
234 microscopy. We performed single particle cryo-EM and 2D-image classification. This
235 confirmed that the trimeric spike protein was properly folded and assembled (Figure 1).



236
237

238 **Figure 1. A.** SDS-PAGE of expressed and purified RBD and spike proteins. Lane: 1,
239 molecular weight marker; 2, cell lysate of expressed RBD; 3, purified RBD; 4, cell lysate
240 of expressed SARS-CoV-2 S; 5, purified spike; 6 and 7, Western blot of purified RBD
241 and spike, respectively. **B and C.** Electron micrographs of negatively stained purified
242 RBD and spike protein, respectively. **D.** 2D class averages from boxed aligned single-
243 particle cryo-EM images of the trimeric spike protein, showing secondary structure
244 elements indicative of proper folding. Box size 28 nm. Scale bars 20 nm 100 nm in B
245 and C, respectively.
246
247 *Validation of micro blood sampling method.*
248 Serum samples are typically separated from intravenously collected blood. To confirm that
249 the finger-prick method neither causes unforeseen complications nor affects assay sensitivity,
250 blood samples from two confirmed SARS-CoV-2 PCR-positive individuals were taken both
251 intravenously and by finger-prick on the same day. Although these samples were collected at
252 least 92 days post exposure, they retained a high antibody titer comparable to positive
253 controls, which were collected 10-30 days post onset of symptoms.
254 The MiniCollect® capillary blood collection tube contains a prefilled volume of a
255 polymer gel with a lithium heparin coagulant, which induces blood clotting and can separate
256 the blood clot from serum by centrifugation. Separated serum from four samples were tested
257 in a dilution series in duplicate on both an RBD-coated ELISA plate and a trimeric spike-coated
258 ELISA plate according to the "step 2" ELISA protocol (*1*) (see Methods and modified plate
259 layout in Supplementary Figure 1C). For both individuals, titers of intravenous and capillary
260 blood were similar on both the RBD-coated and the spike-coated plate (Figure 2).
261



Figure 2: Comparison of serum antibody titers from intravenously collected blood and capillary blood obtained by finger prick. Individuals A and B provided blood samples both intravenously and also by micro-blood collection at least 90 days post exposure. Each sample was tested in duplicate on the same ELISA plate, either coated with SARS-CoV-2 spike RBD (left) or with SARS-CoV-2 trimeric spike protein (right). Each replicate is plotted. Line connects average values. Positive control was pooled serum collected from two SARS-CoV-2 PCR-positive individuals 10-30 days after onset of symptoms. Negative controls were collected from individuals prior to November 2019.

Serological Survey

Overall, 675 sample tubes were collected and processed. Among all the samples received, zero samples showed signal above threshold in both the RBD screening plate and the spike confirmatory plate.

Samples were typically collected, serum separated, and heat-inactivated at the end of each day. Nonetheless, most blood samples can be stored at room temperature in the serum separation tube for several days, in some cases with larger blood volume for up to 1 week.

281 Longer than 1 week is not recommended because the blood begins to dry up. Antibody titers
282 after serum separation have been reported as stable for up to 6 weeks when stored at 4 °C
283 (*8*). Some participants had difficulty collecting their blood by themselves. In such cases, we
284 encouraged participants to visit the nurses in our institute's Health Center for assistance.
285 The results for RBD ELISA step 1 are summarized in Figure 3A. Intensities were scaled
286 with respect to the threshold for each plate. Results were compared with multiple negative
287 controls and a collection of serum samples from SARS-CoV-2 PCR positive individuals. A subset
288 of 63 OIST samples had serum antibody reactivity above the established threshold, and only
289 a few were at the same level as the PCR-positive individuals. Titers from all PCR-positive
290 individuals were above the threshold. Samples from all PCR-positive individuals were taken
291 by capillary blood collection at least one month post onset of symptoms.
292 Results for the final ELISA step 2 are shown in Figure 3B. Of the 63 OIST samples that
293 were positive in RBD step 1, all had serum antibody reactivity below threshold for all 5
294 dilutions when tested against the SARS-CoV-2 trimeric spike protein in step 2, indicating a
295 9.9% false positive rate in the highly sensitive step 1. Samples from all PCR positive individuals
296 were above the threshold for at least two dilutions. Results were classified as "positive"
297 (above threshold), "negative" (below threshold), or "undetermined". The most common
298 cause of an undetermined result was the failure to provide sufficient serum. This was the case
299 for 40 of the 675 samples that we received. If the result was undetermined, the participant
300 was encouraged to pick up another kit and try again.
301 From the SurveyMonkey platform, 206 completed surveys were received, or 31 % of
302 all samples collected. The collective results showed that 17 % of the survey takers believed
303 that they had experienced some COVID-19 symptoms in the past 6 months and 31 % had
304 travelled outside of Okinawa in the past 6 months. The age distribution was as follows: 20-40
305 years old, 60 %; 40-60 years, 36 %; greater than 60 years, 4 %. The gender distribution was
306 roughly equal.
307



Figure 3: Summary of OIST Serological Survey. A. In assay step 1 (anti-RBD ELISA), 63 OIST samples were above the threshold (3 standard deviations above the average negative control). **B.** All positives from step 1 were tested in step 2 (anti-spike ELISA). No OIST samples were above the threshold (4 times the average background). **C.** Step-2 titers were measured at dilutions 1:100, 1:300, 1:900, 1:2700, and 1:8100. Positive controls showed much stronger signal than the OIST samples even at high dilution. The dotted line indicates the respective threshold level. All negative controls are samples taken from patients prior to November 2019. Sera from PCR positive individuals were collected at least 10-30 days post onset of symptoms.

Assay Specificity

The specificity of the Mount Sinai Hospital Clinical Laboratory COVID-19 ELISA Antibody Test has been reported as 100 % for 74 negative control samples (*9*) and the developers demonstrated no cross-reactivity against the common coronavirus strain NL63 (*3*). Of note, as part of the protocol establishing process, we used a SARS-CoV-2 convalescent plasma (NIBSC code 20/130) and human MERS-convalescent serum to confirm the specificity of the assay in both steps. As expected, SARS-CoV-2 convalescent plasma showed strong reactivity in both plates. MERS-convalescent serum, on the other hand, was negative in anti-RBD cross-reactivity, but positive in anti-spike cross-reactivity (Figure 4).

329 To understand the basis of the MERS-convalescent serum cross-reactivity, we performed an
330 amino acid sequence alignment of SARS-CoV-2 spike and MERS-CoV spike protein. Sequence
331 alignment demonstrated that the SARS-CoV-2 RBD shares 18.7 % identity with MERS-CoV RBD,
332 but alignment of the full-length spike sequence demonstrated higher 32.3 % sequence
333 identity between SARS-CoV-2, and MERS-CoV (Supplementary Figure 3).
334



335
336
337 **Figure 4: Titers of SARS-CoV-2 and MERS-CoV convalescent serum in RBD and spike**
338 **ELISA.** Each sample was tested in duplicate on the same plate. Line connects average
339 values. Positive control is pooled serum from two CoV-2 PCR positive individuals 10-
340 30 days after onset of symptoms. Negative control is from a commercial serum pool.
341

342 **Discussion**

343

344 *Micro blood sampling is a good alternative to venous blood collection*

345 Micro blood sampling by finger prick at home avoids unnecessary risk and effort by healthcare
346 workers and allows parallel collection of large numbers of samples within a short period of
347 time. The combination of patient-driven sample self-collection with a standardized highly
348 specific and selective ELISA in a centralized lab improves the reliability of results while keeping

349 costs low. Serum can be separated from whole blood up to 1 week after collection. Provided
350 that temperatures are kept close to ambient temperature, this would allow for shipping of
351 samples from collection site to the testing site by mail. The main bottleneck is serum transfer
352 from collection tube to ELISA plate. This step may be accelerated with a sophisticated
353 integrated liquid handling system. We showed that antibody titers from capillary blood serum
354 are equivalent to titers measured from venous blood (Figure 2). The Infectious Diseases
355 Society of America Guidelines on the Diagnosis of COVID-19 currently make no
356 recommendations for or against the use of capillary blood in serological assays due to a
357 knowledge gap on the subject (*10*). We hope that the success of our study begins to fill this
358 knowledge gap, paving the way for further proof-of-concept studies using capillary blood. Our
359 survey revealed that micro blood sampling of capillary blood is a practical, cost-efficient
360 method using as little as one drop of blood (approximately 30 µL) per sample. Such a small
361 sample volume would even allow testing of newborns using neonatal heel prick.
362
363 *Anonymization and web-based reporting*
364 The web-based platform served as an efficient means to conduct this study anonymously
365 while providing instructions and communicating results to participants. Anonymization was
366 achieved by randomly barcoded samples without the need to enter personal data. From the
367 1,154 staff and students at OIST (as of May 2020), 675 samples were received, of which only
368 41 samples (6.1%) could not be tested due to lack of serum or improper sample collection.
369 The success of our practical web-based method indicates that this method may be used for
370 larger epidemiological studies.
371
372 *Significance of OIST results*
373 The serological survey of students and employees carried out at OIST on Okinawa, Japan, in
374 August 2020 revealed no seroconversion among this small population. The test has reliably
375 identified all previously confirmed PCR-positive individuals and controls, with reactivities as
376 high as 7 times threshold. Our results assert strong confidence in this 2-step assay, which has
377 received FDA-emergency approval (*2*).
378 Okinawa has, thus far, enjoyed moderately low numbers of COVID-19 cases among its
379 population. Other recent serological surveys in Japan, have found seroprevalence as low as
380 0.43 % (among 44,066 employees and business partners of the company Softbank and

381 healthcare workers across Japan) (*11*), 0.1 % (1,971 citizens of Tokyo), 0.03 % (3,009 citizens
382 in Miyagi Prefecture) and 0.17 % (2,970 citizens of Osaka prefecture) (*12*). At such low
383 seroprevalence, high assay specificity is critical to achieving a high predictive value (*13*, *14*).
384 Although accurate estimation of the actual seroprevalence among OIST staff and students
385 (including the 45 % of employees that did not participate in the survey) is not possible,
386 assuming a seroprevalence between 0.03 % (Tokyo) and 0.43 % (Softbank), with a known
387 assay specificity of close to 100 % and a sensitivity of 92.5 % for the Mt. Sinai Antibody Test
388 used here (*9*), we estimate the negative predictivity value of our assay to be greater than
389 99.9%.

390 SARS-CoV, SARS-CoV-2 and other human coronaviruses such as NL63 use aceE2 as
391 receptor (*15*, *16*) mediated by the class-1 fusion protein S before entry through the plasma
392 membrane, or via a clathrin-dependent endosomal pathway (*17*). MERS-CoV utilizes a similar
393 mechanism but uses the dipeptidyl peptidase 4 receptor (dpp4) instead (*18*). Dpp4 does not
394 share sequence and structural similarity to previously identified human coronavirus receptors
395 such as ACE2 or APN (*15*, *16*, *19*). Convalescent plasma samples from SARS-CoV-infected
396 patients have moderate cross-reactivity with SARS-CoV-2 spike protein, but no cross-
397 neutralization (*20*). The assay used here has been shown to have no cross-reactivity with the
398 seasonal human coronavirus NL63 (*3*). Interestingly, when we tested human convalescent
399 serum from MERS patients with our ELISA, we found explicit cross-reactivity between MERS
400 serum and SARS-CoV-2 spike with an antibody titer similar to that of SARS-CoV-2 plasma. Our
401 sequence alignment indicated only 18.7 % sequence identity between SARS-CoV-2 RBD and
402 MERS-CoV RBD. On the other hand, we found 32.3 % identity between SARS-CoV-2 and MERS-
403 CoV spike (S) (Supplementary Figure 3), indicating higher sequence conservation in the other
404 domains of the spike protein, thus providing a possible explanation for the observed cross-
405 reactivity. For a given SARS-CoV-2 convalescent serum sample with an anti-spike titer of
406 >1:1350, the probability of viral neutralization at the FDA-recommended level for
407 convalescent plasma used for COVID-19 treatment (viral neutralization titer ≥1:160), has been
408 found to be ≥80 % (*21*). Our data shows strong MERS cross-reactivity with SARS-CoV-2 spike
409 at titers close to 1:1350. Although most effective neutralizing antibodies against
410 coronaviruses target the RBD, neutralizing antibodies against SARS-CoV-2 S1-N-terminal
411 domain (*22*) and SARS-CoV S2 domain (*23*) have also been identified. Our data suggests that
412 MERS convalescent serum may also contain such neutralizing antibodies against SARS-CoV-2.

Author contributions

M.M., ELISA implementation, validation, analysis. M.M., S.S., N.S., ELISA execution. S.S., test kit development. T.G.K., N.S., protein expression. T.G.K., protein purification. T.G.K., J.H.K., electron microscopy and image analysis. C.B., workflow automation. K.K., sequence alignment. T.R., S.S.J., website design, sample codes. M.N. provided finger-prick validation samples and controls. T.M., medical advice and study ethics. M.C., mentoring and advice, website content, study ethics. M.W. project creation and supervision. M.M., M.W. wrote initial draft. All authors edited and contributed to the final manuscript.

Data availability

Requests for further information or raw data should be directed to the corresponding author.

Acknowledgements

MERS-CoV convalescent sera was kindly provided by Dr Giada Mattiuzzo (NIBSC, United Kingdom), in collaboration with Dr Manki Song (International Vaccine Institute, South Korea) Chungnam National University Hospital, and funded by Coalition for Epidemic Preparedness Innovations (CEPI, Norway). We thank Kieran Deasy and Mouez Lassoued for 3D-printing tube racks. We are grateful to Mahesh Bandi for advice on statistics and to Alejandro Villar Brillones for advice on automation. We thank Chris Wu for developing the website's theme and stylesheets. We thank Pinaki Chakraborty for providing the time and expertise of his technician C.B. This work was supported by the Platform Project for Supporting Drug Discovery and Life Science Research (BINDS) from AMED, under grant number JP18am0101076 (to M.W.). We acknowledge financial support by OPG for a larger serological study, as well as direct funding from OIST.

References

1. D. Stadlbauer *et al.*, SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a

445 Serological Assay, Antigen Production, and Test Setup. *Curr. Protoc. Microbiol.* **57**
446 (2020), doi:10.1002/cpmc.100.
447 2. "Accelerated emergency use authorization (EUA) summary COVID-19 ELISA IGG
448 antibody test (Mount Sinai Laboratory)" (2020), (available at
449 https://www.fda.gov/media/137029/download).
450 3. F. Amanat *et al.*, A serological assay to detect SARS-CoV-2 seroconversion in humans.
451 *Nat. Med.* **26**, 1033–1036 (2020).
452 4. S. Q. Zheng *et al.*, MotionCor2: anisotropic correction of beam-induced motion for
453 improved cryo-electron microscopy. *Nat. Methods*. **14**, 331–332 (2017).
454 5. J. Zivanov *et al.*, New tools for automated high-resolution cryo-EM structure
455 determination in RELION-3. *Elife*. **7** (2018), doi:10.7554/eLife.42166.
456 6. S. Pickering *et al.*, Comparative assessment of multiple COVID-19 serological
457 technologies supports continued evaluation of point-of-care lateral flow assays in
458 hospital and community healthcare settings. *PLOS Pathog.* **16**, e1008817 (2020).
459 7. D. G. Altman, j. M. Bland, Statistics Notes: Diagnostic tests 2: Predictive values. *BMJ*.
460 **309**, 102 (1994).
461 8. D. Stadlbauer *et al.*, Anti-SARS-CoV -2 Spike Antibodies are Stable in Convalescent
462 Plasma when Stored at 4° Celsius for at Least 6 Weeks . *Transfusion* (2020),
463 doi:10.1111/trf.16047.
464 9. A. Wajnberg *et al.*, *medRxiv*, in press, doi:10.1101/2020.07.14.20151126.
465 10. K. E. Hanson *et al.*, Infectious Diseases Society of America Guidelines on the Diagnosis
466 of COVID-19:Serologic Testing. *Clin. Infect. Dis.* (2020), doi:10.1093/cid/ciaa1343.
467 11. "Softbank Group Antibody Test Results" (2020), (available at
468 https://group.softbank/system/files/pdf/antibodytest.pdf).
469 12. "Tokyo Osaka and Miyagi Prefecture Antibody Possession Survey Results" (2020),
470 (available at https://www.mhlw.go.jp/content/10906000/000640184.pdf).
471 13. J. D. Whitman *et al.*, Evaluation of SARS-CoV-2 serology assays reveals a range of test
472 performance. *Nat. Biotechnol.* **38**, 1174–1183 (2020).
473 14. N. C. Brownstein, Y. A. Chen, *medRxiv Prepr. Serv. Heal. Sci.*, in press,
474 doi:10.1101/2020.06.04.20122358.
475 15. W. Li *et al.*, Angiotensin-converting enzyme 2 is a functional receptor for the SARS
476 coronavirus. *Nature*. **426**, 450–454 (2003).

477 16. F. Li, W. Li, M. Farzan, S. C. Harrison, Structural biology: Structure of SARS coronavirus
478 spike receptor-binding domain complexed with receptor. *Science (80-.).* **309**, 1864–
479 1868 (2005).
480 17. T. Tang, M. Bidon, J. A. Jaimes, G. R. Whittaker, S. Daniel, Coronavirus membrane
481 fusion mechanism offers a potential target for antiviral development. *Antiviral Res.*
482 **178** (2020), , doi:10.1016/j.antiviral.2020.104792.
483 18. V. S. Raj *et al.*, Dipeptidyl peptidase 4 is a functional receptor for the emerging human
484 coronavirus-EMC. *Nature*. **495**, 251–254 (2013).
485 19. N. Wang *et al.*, Structure of MERS-CoV spike receptor-binding domain complexed
486 with human receptor DPP4. *Cell Res.* **23**, 986–993 (2013).
487 20. H. Lv *et al.*, Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV
488 Infections. *Cell Rep.* **31** (2020), doi:10.1016/j.celrep.2020.107725.
489 21. E. Salazar *et al.*, Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and
490 receptor binding domain IgG correlate with virus neutralization. *J. Clin. Invest.* (2020),
491 doi:10.1172/jci141206.
492 22. X. Chi *et al.*, A neutralizing human antibody binds to the N-terminal domain of the
493 Spike protein of SARS-CoV-2. *Science (80-.).* **369**, 650–655 (2020).
494 23. J. Duan *et al.*, A human SARS-CoV neutralizing antibody against epitope on S2 protein.
495 *Biochem. Biophys. Res. Commun.* **333**, 186–193 (2005).
496



Supplemental Figure 1: Antibody Survey Sample Collection Kit and Plate Design. A. Each blood sampling kit included BD Microtainer® contact-activated lancet (Becton Dickison, USA), 0.8 ml volume blood collection tube containing a coagulant and a separator (Greiner bio-one), packaged alcohol wipes, adhesive bandage, and sticker with an identification barcode and QR code. **B.** Front page of OIST Antibody Test website. **C.** Plate designs used in the ELISA. Plates are modified versions of those described previously (*1*).



Supplemental Figure 2: Basic user flow followed by participants to view test results and answer optional survey

```
SARS-CoV-2   ----MFVFLVLL-P----------LVSSQCVNLTTRT-----QLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSN---VTWFHAIHVSGTNGTKRF----DNPVLPFNDGVYFA  93
MERS         MIHSVFLLMFLLTPTESYVDVGPDSVKSACIEVDIQQTFFDKTWPRPIDVSKADGIIYPQGRTYSNITITYQGLF-PYQGDHGDMYVYSAGHATGTTPQKLFVANYSQDVKQFANGFVVR  119
                 :*:::.** *           *.* *:::  :        *     * : *: **:    *.:  : *.** *: .:   :  : * *.:**.  * *    .: *  * :*. .

SARS-CoV-2   S-------------TEK----SNIIRGWIFGTTLDSKT---------QSLLIVNNATNVVIKVCEFQFCNDPFLGV-----------YYHK---------NNKSWMESEFRVYSSANNC  166
MERS         IGAAANSTGTVIISPSTSATIRKIYPAFMLGSSVGNFSDGKMGRFFNHTLVLLPDGCGTLLRA--FYCILEPRSGNHCPAGNSYTSFATYHTPATDCSDGNYNRNASLNSFKEYFNLRNC  237
                          ..     :*  .:::*:::.. :          ::*::: :. ..:::.  *    :*  *                **.           *:.   ..*: * . .**

SARS-CoV-2   TFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVR----DLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNEN  282
MERS         TFMYTYNITE-----------------DEILEWFGITQTAQGVHLFSSRYVDLYGG--NMFQFATLPVYDTIKYYSII---PHSIRSIQSDRKAW----AAFYVYKLQPLTFLLDFSVD  330
             ** *. :                      .:*  :* * ..   ::*.     **  *   :  :. **:  .*. :. :    :*  :  .. ..*    **:**  *** ****.:. :

SARS-CoV-2   GTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVI  402
MERS         GYIRRAIDCGFNDLSQLHCSYESFDVESGVYSVSSFEAKPSGSVVEQAE-GVECDFSPLLSGT-PPQVYNFKRLVFTNCNYNLTKLLSLFSVNDFTCSQISPAAIASNCYSSLILDYFSY  448
             * *  *:**.:: **: :*: :** **.*:*..*.*..:*: *:*.  :    * *. ::..*   .** ::*  ::**  : : * .  *.. *.*  :**: : . *::.:  * *

SARS-CoV-2   RGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGN--YNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCY---------FPLQSYGFQPTNGVGYQPYRV  510
MERS         PLSMKSDLSVSSAGPISQFNYKQSFSNPTCLILATVPHNLTTITKPLKYSYINKCSR--FLSDDRTEVPQLVNANQYSPCVSIVPSTVWEDGDYYRKQLSPLEGGGWLVASGSTVAMTEQ  566
               .   ::: ..:* *:::***   .   *:*  .  :  :.:     *.*: :  *   *.  . ::   :     :** .:   . :           **:. *:  :.*      .

SARS-CoV-2   VVLSFEL----LHAPATVCGP-----KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDA-VRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEV  620
MERS         LQMGFGITVQYGTDTNSVCPKLEFANDTKIASQLGNCVEYSLYGVSGRGVFQNCTAVGVRQQRFVYDAYQNLVGYYSDD--GNYYCLRACVSVPVSVIYD--KETKTHATLFGSVACEHI  682
             : :.* :         :**       ...     .:**::.: *::* **: :..   :  *:*  *  :.  .   *    :   :  *    ****    : ::  *.*: .* * .:

SARS-CoV-2   PVAIHADQL--TPTWRVYSTGSNVFQTRAGCLIGAEHVN-NSYECDIPIGAGICASYQTQTNS-PASVASQ------SIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTK  730
MERS         SSTMSQYSRSTRSMLKRRDSTYGPLQTPVGCVLGLVNSSLFVEDCKLPLGQSLCALPDTPSTLTPRSVRSVPGEMRLASIAFNHPIQ-VDQLNSSYFKLSIPTNFSFGVTQEYIQTTIQK  801
               ::   .       :  .:  . :** .**::*  : .    :*.:*:* .:**  :* :.  * ** *       : **:.  :   :.:  *  .::*****::.** * : .:: *

SARS-CoV-2   TSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFN-FSQILP---DPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLG--DIAAR  844
MERS         VTVDCKQYVCNGFQKCEQLLREYGQFCSKINQALHGANLRQDDSVRNLFASVKSSQSSPIIPGFGGDFNLTLLEPVSISTGSRSARSAIEDLLFDKVTIADPGYMQGYDDCMQQGPASAR  921
             .:***. *:*..  :*.:** :**.**:::*:** *  :.**...:::**.**.  .:* * .***   :: : *   . .. * ** ******:***:** *::: *.**:     :**

SARS-CoV-2   DLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLS  964
MERS         DLICAQYVAGYKVLPPLMDVNMEAAYTSSLLGSIAGVGWTAGLSSFAAIPFAQSIFYRLNGVGITQQVLSENQKLIANKFNQALGAMQTGFTTTNEAFHKVQDAVNNNAQALSKLASELS  1041
             ****** . * .*****:  :* * ***:**..    *** * .:   **** .: **:**:*:**:** ********:**.*:* :* .:::* .*: *:**.**:*****..*..:**

SARS-CoV-2   SNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKA  1084
MERS         NTFGAISASIGDIIQRLDVLEQDAQIDRLINGRLTTLNAFVAQQLVRSESAALSAQLAKDKVNECVKAQSKRSGFCGQGTHIVSFVVNAPNGLYFMHVGYYPSNHIEVVSAYGLCDAANP  1161
             ..*****: :.**:.*** :* :.******.*** :*:::*:***:*: .   **:**  *:.*** .**** .***:* *::**  .**:*: *:** * *::. :...* .:*. .:

SARS-CoV-2   ---HFPREGVFVSN-----GTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQ--PELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESL  1194
MERS         TNCIAPVNGYFIKTNNTRIVDEWSYTGSSFYAPEPITSLNTKYVAPQVTYQNI-STNLPPPLLGNSTGIDFQDELDEFFKNVSTSIPNFGSLTQINTTLLDLTYEMLSLQQVVKALNESY  1280
                  * :* *:..       .*  *  .** *: **: **   .   .  .* ...:  **       .*::***::*** ::   ::*.:: **::::::  *:  *::*.* ****

SARS-CoV-2   IDLQELGKYEQYIKWP-------------------------------------------------------  1210
MERS         IDLKELGNYTYYNKWPWYIWLGFIAGLVALALCVFFILCCTGCGTNCMGKLKCNRCCDRYEEYDLEPHKVHVH  1353
             ***:***:*  * ***
```

Supplementary Figure 3: Amino acid sequence alignment of spike (S) proteins from SARS-CoV-2 and MERS-CoV. RBD regions (SARS-CoV-2, residue 319-541 and MERS, residue 367-606) are highlighted in red.